<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01190358</url>
  </required_header>
  <id_info>
    <org_study_id>200917488</org_study_id>
    <nct_id>NCT01190358</nct_id>
  </id_info>
  <brief_title>Grape Seed Extract and Postprandial Oxidation and Inflammation</brief_title>
  <acronym>GSEMetS</acronym>
  <official_title>Grape Seed Extract and Postprandial Oxidation and Inflammation: A Pilot Study in People With the Metabolic Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether taking grape seed extract prior to eating a&#xD;
      high fat meal will reduce the inflammatory response in people with the metabolic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether taking grape seed extract prior to eating a&#xD;
      high fat meal will reduce the inflammatory response in people with the metabolic syndrome. If&#xD;
      this extract is shown to mitigate the inflammatory response induced by a high fat meal, it&#xD;
      could potentially aid in postponing of the diagnosis of diabetes or other chronic diseases&#xD;
      associated with high levels of inflammation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2010</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modification of the postprandial inflammatory response.</measure>
    <time_frame>7 hours</time_frame>
    <description>Analysis of inflammatory markers known to increase following a meal high in fat (~40% kcal from fat). Markers to be analyzed will include the following:&#xD;
Serum lipids&#xD;
Oxidized LDL&#xD;
Hs-CRP&#xD;
TNFα&#xD;
IL1&#xD;
IL6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic response to a high fat meal.</measure>
    <time_frame>7 hours</time_frame>
    <description>Assay for the insulin and glucose response generated from consumming a high fat meal (~40% of kcal from fat).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sugar pill</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grape seed extract</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>300mg of grape seed extract.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill containing maltodextrin.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo, non-active components</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Grape seed extract</intervention_name>
    <description>Meganatural Gold® contains 300mg of grape seed extract.</description>
    <arm_group_label>Grape seed extract</arm_group_label>
    <other_name>Active, Meganatural Gold®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The metabolic syndrome will be diagnosed on the basis of having a combination of any 3 of&#xD;
        the following factors:&#xD;
&#xD;
          1. Waist circumference of ≥ 40 inches (men) or ≥ 35 inches (women)&#xD;
&#xD;
          2. Elevated triglycerides ≥150mg/dl&#xD;
&#xD;
          3. HDL cholesterol of &lt; 40mg/dl (men) or &lt; 50mg/dl (women)&#xD;
&#xD;
          4. Elevated blood pressure of ≥ 130/85mmHg&#xD;
&#xD;
          5. Fasting glucose of &gt; 100mg/dL&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Smokers&#xD;
&#xD;
          -  Female subjects who are pregnant or lactating&#xD;
&#xD;
          -  Subjects taking any medications that would interfere with outcomes of the study i.e.&#xD;
             lipid lowering medications, anti-inflammatory drugs (i.e. ibuprofen), dietary&#xD;
             supplements&#xD;
&#xD;
          -  Subjects with any known allergy or intolerance to foods involved in the study&#xD;
             (cantaloupe, egg, dairy, wheat, grape seed extract)&#xD;
&#xD;
          -  Subjects who are actively trying to lose weight&#xD;
&#xD;
          -  Subjects with unusual dietary habits (i.e. pica, anorexia nervosa, extreme food&#xD;
             restriction, binging and/or purging disorders)&#xD;
&#xD;
          -  Subjects who are addicted to drugs or alcohol or who are &lt;1 year recovery program&#xD;
&#xD;
          -  Subjects who present with significant psychiatric or neurological disturbances as&#xD;
             determined by the primary investigator (i.e. uncontrolled bipolar disorder)&#xD;
&#xD;
          -  Subjects with documented atherosclerotic disease, inflammatory disease, diabetes&#xD;
             mellitus, uncontrolled hypertension (≥ 140/90mmHg), liver and kidney disease as&#xD;
             identified by routine blood tests (chemistry panels). These subjects will be referred&#xD;
             to their primary care doctor for further care.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chulani T Kappagoda, M.D., Ph. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Davis (Academic Surge, Ragle Human Nutrition Research Facility)</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Hospital, Mather</name>
      <address>
        <city>Mather</city>
        <state>California</state>
        <zip>95655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>August 25, 2010</study_first_submitted>
  <study_first_submitted_qc>August 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2010</study_first_posted>
  <last_update_submitted>July 17, 2017</last_update_submitted>
  <last_update_submitted_qc>July 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Grape Seed Extract</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

